NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01
October 24 2023 - 10:56AM
Dow Jones News
By Chris Wack
NKGen Biotech shares were up 8% to $3.25 after the company said
the U.S. Food and Drug Administration has cleared its
investigational new drug application for SNK01 natural killer cell
therapy for treatment of moderate Alzheimer's disease.
The stock hit its 52-week low of $2.86 on Oct. 13, and is down
67% in the past 12 months.
SNK01 is an autologous, non-genetically modified NK cell product
that has enhanced cytotoxicity and activating receptor
expression.
The company said this approved trial of 30 patients with
moderate Alzheimer's will hopefully begin before the end of this
year, and the first interim data is expected in early third quarter
of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 24, 2023 10:41 ET (14:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
NKGen Biotech (NASDAQ:NKGN)
Historical Stock Chart
From Feb 2025 to Mar 2025
NKGen Biotech (NASDAQ:NKGN)
Historical Stock Chart
From Mar 2024 to Mar 2025
